Congestive heart failure acute pharmacotherapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 3: Line 3:


==Overview==
==Overview==
==Acute Pharmacotherapy==
The goals of acute treatment include:
The goals of acute treatment include:
* Reduce [[preload]]
* Reduce [[preload]]
Line 10: Line 9:
* Improve [[cardiac contractility]]
* Improve [[cardiac contractility]]


===Mainstays of Therapy===
==Mainstays of Therapy==
*Oxygen to improve oxygenation if [[hypoxemia]] is present. [[Positive airway pressure|Continuous positive airway pressure]] may be applied using a face mask; this has been shown to improve symptoms more quickly than oxygen therapy alone,<ref>{{cite journal |author=Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J |title=Noninvasive ventilation in acute cardiogenic pulmonary edema |journal=N. Engl. J. Med. |volume=359 |issue=2 |pages=142–51 |year=2008 |month=July |pmid=18614781|doi=10.1056/NEJMoa0707992}}</ref> and has been shown to reduce the risk of death.<ref>{{cite journal |author=Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD |title=Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis |journal=Lancet |volume=367 |issue=9517 |pages=1155–63 |year=2006 |month=April |pmid=16616558|doi=10.1016/S0140-6736(06)68506-1}}</ref><ref>{{cite journal |author=Weng CL |title=Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema |journal=Ann. Intern. Med. |volume=152 |issue=9 |pages=590–600 |year=2010 |month=May |pmid=20439577 |doi=10.1059/0003-4819-152-9-201005040-00009 |url= |author-separator=, |author2=Zhao YT |author3=Liu QH |display-authors=3 |last4=Fu |first4=CJ |last5=Sun |first5=F |last6=Ma |first6=YL |last7=Chen |first7=YW |last8=He |first8=QY}}</ref> Severe [[respiratory failure]] requires treatment with [[endotracheal intubation]] and [[mechanical ventilation]].
*Oxygen to improve oxygenation if [[hypoxemia]] is present. [[Positive airway pressure|Continuous positive airway pressure]] may be applied using a face mask; this has been shown to improve symptoms more quickly than oxygen therapy alone,<ref>{{cite journal |author=Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J |title=Noninvasive ventilation in acute cardiogenic pulmonary edema |journal=N. Engl. J. Med. |volume=359 |issue=2 |pages=142–51 |year=2008 |month=July |pmid=18614781|doi=10.1056/NEJMoa0707992}}</ref> and has been shown to reduce the risk of death.<ref>{{cite journal |author=Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD |title=Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis |journal=Lancet |volume=367 |issue=9517 |pages=1155–63 |year=2006 |month=April |pmid=16616558|doi=10.1016/S0140-6736(06)68506-1}}</ref><ref>{{cite journal |author=Weng CL |title=Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema |journal=Ann. Intern. Med. |volume=152 |issue=9 |pages=590–600 |year=2010 |month=May |pmid=20439577 |doi=10.1059/0003-4819-152-9-201005040-00009 |url= |author-separator=, |author2=Zhao YT |author3=Liu QH |display-authors=3 |last4=Fu |first4=CJ |last5=Sun |first5=F |last6=Ma |first6=YL |last7=Chen |first7=YW |last8=He |first8=QY}}</ref> Severe [[respiratory failure]] requires treatment with [[endotracheal intubation]] and [[mechanical ventilation]].
*[[Diuretics]] reduce [[preload]] and reduce intravascular volume. Intravenous diuretics are often required in the acute setting.  If high doses of furosemide are inadequate, boluses or continuous infusions of [[bumetanide]] may be preferred. These [[loop diuretics]] may be combined with [[thiazide diuretics]] such as oral [[metolazone]] or intravenous [[chlorthiazide]] for a synergistic effect. Intravenous preparations are preferred because of more predictable absorption. When a patient is extremely fluid overloaded, they can develop intestinal edema as well, which can affect enteral absorption of medications.
*[[Diuretics]] reduce [[preload]] and reduce intravascular volume. Intravenous diuretics are often required in the acute setting.  If high doses of furosemide are inadequate, boluses or continuous infusions of [[bumetanide]] may be preferred. These [[loop diuretics]] may be combined with [[thiazide diuretics]] such as oral [[metolazone]] or intravenous [[chlorthiazide]] for a synergistic effect. Intravenous preparations are preferred because of more predictable absorption. When a patient is extremely fluid overloaded, they can develop intestinal edema as well, which can affect enteral absorption of medications.
Line 16: Line 15:
*[[Morphine]] reduces [[preload]], reduces [[catecholamines]], and reduces the stimulation by stretch receptors in the lung thereby improving symptoms of [[dyspnea]].
*[[Morphine]] reduces [[preload]], reduces [[catecholamines]], and reduces the stimulation by stretch receptors in the lung thereby improving symptoms of [[dyspnea]].


===More Aggressive Pharmacotherapy===
==More Aggressive Pharmacotherapy==
*[[Nitroprusside]] reduces [[afterload]] and reduces [[preload]]
*[[Nitroprusside]] reduces [[afterload]] and reduces [[preload]]


Line 24: Line 23:
*[[Dopamine]] increases blood pressure and increases renal perfusion at low doses
*[[Dopamine]] increases blood pressure and increases renal perfusion at low doses
*[[Nesiritide]] reduces [[afterload]] and reduces [[preload]] and can be used if other therapies have not been effective.
*[[Nesiritide]] reduces [[afterload]] and reduces [[preload]] and can be used if other therapies have not been effective.
===Ultrafiltration===
* [[Ultrafiltration]] has been associated with a reduced incidence of hospitalization compared with diuretics in the UNLOAD trial. There was no difference in mortality.
* Ultrafiltration removes plasma water from whole blood. Possible benefits of ultrafiltration include:
*Provides fluid regulation
:* Relieve [[pulmonary edema]]
:* Reduce [[ascites]] and/or [[peripheral edema]]
:* Hemodynamic stabilization
:* Improve oxygenation
:* Facilitates blood product replacement without excess volume
:* Enable [[parenteral nutritional]] support without excess volume
* Improves solute regulation
:* Correct [[acid-base balance]]
:* Correct serum sodium content
:* Eliminate myocardial depressant factors or known toxins
:* Correct [[uremia]]
:* Correct [[hyperkalemia]]
:* Correct other [[electrolyte disturbances]]
* Helps to establish homeostasis
:* Reset [[water omostat]]
:* Restore diuretic responsiveness
:* Reduce [[neurohormonal activation]]
==Chronic Pharmacotherapy==
==Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)==
* Cardiac resynchronization therapy should only be undertaken if the blood pressure is low and if the heart failure medicines have been optimized
* CRT is indicated for symptomatic patients with NYHA III-IV heart failure and wide QRS complex (>120ms) who are him normal sinus rhythm.
* 70% of patients receiving synchronous ventricular contraction report significant symptomatic improvements.
==ACC / AHA Guidelines - Recommendations for Cardiac Resynchronization Therapy in Patients with Severe Systolic Heart Failure (DO NOT EDIT)<ref name="pmid18483207">{{cite journal |author=Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Smith SC, Jacobs AK, Adams CD, Anderson JL, Buller CE, Creager MA, Ettinger SM, Faxon DP, Halperin JL, Hiratzka LF, Hunt SA, Krumholz HM, Kushner FG, Lytle BW, Nishimura RA, Ornato JP, Page RL, Riegel B, Tarkington LG, Yancy CW |title=ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons |journal=[[Circulation]] |volume=117 |issue=21 |pages=e350–408 |year=2008 |month=May |pmid=18483207 |doi=10.1161/CIRCUALTIONAHA.108.189742 |url=http://circ.ahajournals.org/cgi/pmidlookup?view=long&pmid=18483207 |issn= |accessdate=2011-01-15}}</ref>==
{{cquote|
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]====
'''1.'''  For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and sinus rhythm, CRT with or without an ICD is indicated for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms with optimal recommended medical therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: A]])
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIa]]====
'''1.''' For patients who have LVEF less than or equal to 35%, a QRS duration greater than or equal to 0.12 seconds, and AF, CRT with or without an ICD is reasonable for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms on optimal recommended medical therapy. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])
'''2.''' For patients with LVEF less than or equal to 35% with NYHA functional Class III or ambulatory Class IV symptoms who are receiving optimal recommended medical therapy and who have frequent dependence on ventricular pacing, CRT is reasonable. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])
====[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]====
'''1.''' For patients with LVEF less than or equal to 35% with NYHA functional Class I or II symptoms who are receiving optimal recommended medical therapy and who are undergoing implantation of a permanent pacemaker and/or ICD with anticipated frequent ventricular pacing, CRT may be considered. ([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: C]])}}
==Implantation of Intracardiac Defibrillator==
*50% of heart failure patients die of [[sudden cardiac death]].
*ICDs are indicated for patients with previous myocardial infarction and LVEF <30%, sustained ventricular tachycardia, inducible ventricular tachycardia.
*Morbidity/mortality benefit of ICD placement vs. anti-arrhythmic drug therapy is controversial.
==Cardiac Surgery==
* Resection of non-viable myocardium or aneurymectoymay be an option to improve left ventricular geometry
* Revascularization without resection of non-viable myocardium may be helpful if there is hibernating myocardium
==Left Ventricular Assist Devices (LVADs)==
* LVADs are temporary devices to bridge end stage patients to cardiac transplantation.
* The use of LVADs as a destination device rather than as a bridge is investigational at present
==Cardiac Transplantation==
* Cardiac transplantation is reserved for patients with end-stage congestive heart failure despite all interventions.
*:AHA/ACC Guidelines: Indications for heart transplantation:
*::Any hemodynamic compromise due to heart failure.
*::Requiring IV inotropic support to maintain adequate organ perfusion.
*::Peak Vo2 <10 ml/kg/min.
*::NYHA Class IV symptoms not amenable to any other intervention.
*::Recurrence of symptomatic ventricular arrhythmias refractory to all therapeutic intervention.
* 80% 1 year survival, and 60% 5 year survival.
* Lifelong immunosuppressive therapy to prevent (or postpone) rejection, increased risk for opportunistic infections and malignancies.
==Invasive Monitoring==
* Based upon the results of the ESCAPE trial, there is no benefit in clinical outcomes with the use of a pulmonary artery line in patients with decompensated CHF.
==Obstructive Sleep Apnea in the Patient with CHF==
*[[Central sleep apnea]] in the patient with CHF is due to the compensatory [[respiratory alkalosis]] that is present in the patient with CHF and [[tachypnea]]
==Exercise and Daily Activities==
* Patient should have uninterrupted exercise at least four days a week including a walking program.
* Patients with heart failure should avoid weightlifting which increases [[afterload]].
* The patient should not routinely lift more than 20 pounds, again which may increase [[afterload]]. 
* Patients can continue their sexual activity. Some patients take 2.5 or 5.0 mg of sublingual [[nitroglycerine]] before sexual activity.


==References==
==References==

Revision as of 02:42, 4 April 2012

Congestive Heart Failure Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Systolic Dysfunction
Diastolic Dysfunction
HFpEF
HFrEF

Causes

Differentiating Congestive heart failure from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Clinical Assessment

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Cardiac MRI

Echocardiography

Exercise Stress Test

Myocardial Viability Studies

Cardiac Catheterization

Other Imaging Studies

Other Diagnostic Studies

Treatment

Invasive Hemodynamic Monitoring

Medical Therapy:

Summary
Acute Pharmacotherapy
Chronic Pharmacotherapy in HFpEF
Chronic Pharmacotherapy in HFrEF
Diuretics
ACE Inhibitors
Angiotensin receptor blockers
Aldosterone Antagonists
Beta Blockers
Ca Channel Blockers
Nitrates
Hydralazine
Positive Inotropics
Anticoagulants
Angiotensin Receptor-Neprilysin Inhibitor
Antiarrhythmic Drugs
Nutritional Supplements
Hormonal Therapies
Drugs to Avoid
Drug Interactions
Treatment of underlying causes
Associated conditions

Exercise Training

Surgical Therapy:

Biventricular Pacing or Cardiac Resynchronization Therapy (CRT)
Implantation of Intracardiac Defibrillator
Ultrafiltration
Cardiac Surgery
Left Ventricular Assist Devices (LVADs)
Cardiac Transplantation

ACC/AHA Guideline Recommendations

Initial and Serial Evaluation of the HF Patient
Hospitalized Patient
Patients With a Prior MI
Sudden Cardiac Death Prevention
Surgical/Percutaneous/Transcather Interventional Treatments of HF
Patients at high risk for developing heart failure (Stage A)
Patients with cardiac structural abnormalities or remodeling who have not developed heart failure symptoms (Stage B)
Patients with current or prior symptoms of heart failure (Stage C)
Patients with refractory end-stage heart failure (Stage D)
Coordinating Care for Patients With Chronic HF
Quality Metrics/Performance Measures

Implementation of Practice Guidelines

Congestive heart failure end-of-life considerations

Specific Groups:

Special Populations
Patients who have concomitant disorders
Obstructive Sleep Apnea in the Patient with CHF
NSTEMI with Heart Failure and Cardiogenic Shock

Congestive heart failure acute pharmacotherapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Congestive heart failure acute pharmacotherapy

CDC on Congestive heart failure acute pharmacotherapy

Congestive heart failure acute pharmacotherapy in the news

Blogs on Congestive heart failure acute pharmacotherapy

Directions to Hospitals Treating Congestive heart failure acute pharmacotherapy

Risk calculators and risk factors for Congestive heart failure acute pharmacotherapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The goals of acute treatment include:

Mainstays of Therapy

More Aggressive Pharmacotherapy

If the patient's circulatory volume is adequate but there is persistent evidence of inadequate end-organ perfusion, inotropes may be administered.

References

  1. Gray A, Goodacre S, Newby DE, Masson M, Sampson F, Nicholl J (2008). "Noninvasive ventilation in acute cardiogenic pulmonary edema". N. Engl. J. Med. 359 (2): 142–51. doi:10.1056/NEJMoa0707992. PMID 18614781. Unknown parameter |month= ignored (help)
  2. Peter JV, Moran JL, Phillips-Hughes J, Graham P, Bersten AD (2006). "Effect of non-invasive positive pressure ventilation (NIPPV) on mortality in patients with acute cardiogenic pulmonary oedema: a meta-analysis". Lancet. 367 (9517): 1155–63. doi:10.1016/S0140-6736(06)68506-1. PMID 16616558. Unknown parameter |month= ignored (help)
  3. Weng CL; Zhao YT; Liu QH; et al. (2010). "Meta-analysis: Noninvasive ventilation in acute cardiogenic pulmonary edema". Ann. Intern. Med. 152 (9): 590–600. doi:10.1059/0003-4819-152-9-201005040-00009. PMID 20439577. Unknown parameter |month= ignored (help); Unknown parameter |author-separator= ignored (help)


Template:WikiDoc Sources